Xuelan Zuo

机构：Wuhan University, Zhongnan Hospital of Wuhan University · ORCID：0000-0002-8577-347X

发表论文 49 篇 · 总被引 824 次 · h-index 13

代表论文

• SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial (2022 · The Lancet Haematology · 被引 46)
• A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera (2023 · Experimental Hematology and Oncology · 被引 34)
• Efficacy and Safety of the Biosimilar IBI301 Plus Standard CHOP (I-CHOP) in Comparison With Rituximab Plus CHOP (R-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Randomized, Double-Blind, Parallel-Group, Phase 3 Trial (2021 · Advances in Therapy · 被引 19)
• Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b (2024 · British Journal of Haematology · 被引 17)
• Efficacy and safety of QL0911 in adult patients with chronic primary immune thrombocytopenia: A multicenter, randomized, double-blind, placebo-controlled, phase III trial (2023 · Journal of Translational Internal Medicine · 被引 13)
• Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study (2025 · The Lancet Haematology · 被引 9)